Dr. Krasnow joins TherapeuticsMD from Intarcia Therapeutics, where as Chief Safety Officer he was responsible for managing and conducting ongoing safety surveillance on the Intarcia Therapeutics' products, including its lead diabetes product. He also provided scientific input to leverage Intarcia Therapeutics' technology across different clinical applications.Prior to Intarcia Therapeutics, at Eisai Pharmaceuticals, Dr. Krasnow was promoted to Vice President and Chief Medical Officer of its Frontier Business Unit, where he led clinical development, provided clinical guidance to discovery projects and evaluated in-licensing opportunities. He previously spent over four years in the areas of immunology and metabolism at Hoffman-LaRoche, where as the Clinical Science Leader he led the analysis, reporting and presentation of the clinical data resulting in global product approvals for a monoclonal antibody to the interleukin-6 receptor Actemra ® (Tocilizumab), as well as the clinical development and medical marketing of Boniva ® (Ibandronate). He also worked at Novartis as the Senior Medical Director in the Arthritis and Bone Division leading to the registration of Reclast ® (Zoledronic Acid) for Paget’s disease and osteoporosis. During his four year tenure as Medical Director of Pfizer’s Global Prescription Business, he managed clinical and medical marketing programs for contraceptive and hormone replacement products. At Organon, he rose to Medical Director, Endocrinology and Women’s Health, and was the Clinical Lead for FDA interactions with Antagon ® (Ganirelix) and Mircette ®. He also worked at Deloitte Consulting as a Senior Consultant in Pharmaceutical and Managed Care and as a Medical Advisor at Blue Cross of Western Pennsylvania.
TherapeuticsMD Appoints Joel S. Krasnow, M.D. As Chief Scientific Officer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.